Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases.
Toman D, Jorda R, Ajani H, Kryštof V, Cankař P.
Med Chem · journal article · DOI 10.2174/1573406417666210806095710 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för CAN-508. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarSulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
Said MA, Eldehna WM, Nocentini A, Fahim SH, Bonardi A, Elgazar AA, Kryštof V, Soliman DH, Abdel-Aziz HA, Gratteri P, Abou-Seri SM, Supuran CT.
Eur J Med Chem · evaluation study; journal article · DOI 10.1016/j.ejmech.2019.112019Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency.
Shawky AM, Abourehab MAS, Abdalla AN, Gouda AM.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.111780Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L, Tang Y, Xiao Z.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2018.02.054Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling.
Pisár M, Schütznerová E, Hančík F, Popa I, Trávníček Z, Cankař P.
Molecules · research-article; journal article · DOI 10.3390/molecules23010149Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.15645Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R, Schütznerová E, Cankař P, Brychtová V, Navrátilová J, Kryštof V.
Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2015.03.025Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Jorda R, Navrátilová J, Hušková Z, Schütznerová E, Cankař P, Strnad M, Kryštof V.
Chem Biol Drug Des · research support, non-u.s. gov't; journal article · DOI 10.1111/cbdd.12330Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA, Noble ME.
J Med Chem · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/jm301495vThe CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
Baumli S, Hole AJ, Noble ME, Endicott JA.
ACS Chem Biol · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1021/cb2004516The selective P-TEFb inhibitor CAN508 targets angiogenesis.
Kryštof V, Rárová L, Liebl J, Zahler S, Jorda R, Voller J, Cankař P.
Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2011.06.035Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.
Wang S, Fischer PM.
Trends Pharmacol Sci · review; journal article · DOI 10.1016/j.tips.2008.03.0034-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm0605740